Summit Therapeutics Inc.
Robert W Duggan (Co-Chief Executive Officer) reports SMMT insider transactions
About this filing
Summit Therapeutics Inc. (SMMT) filed Form 4 (insider transaction) with the SEC on Nov 16, 2026. Form 4 reports a company insider’s trades in the company’s shares.
Key facts
- Insider
- Robert W Duggan · Co-Chief Executive Officer, Director
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Nov 16, 2026 | M · exercise or conversion of a derivativeFootnotes F1, F2 | +500,000 | $1.06 | $530,000.00 | 531,000 | Indirect (By Spouse) |
| Nov 16, 2026 | M · exercise or conversion of a derivativeStock Option (right to buy)Footnotes F1, F3 | −500,000 | $0.00 | $0.00 | 800,000 | Indirect (By Spouse) |
Footnotes
- F1 On November 16, 2026, the Spouse of Reporting Person exercised an option to purchase 500,000 shares of the Issuer's common stock at an exercise price of $1.06 per share.
- F2 The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
- F3 The option was granted to the Spouse of Reporting Person on June 28, 2022, subject to certain performance criteria. On August 23, 2024, based on satisfaction of certain performance criteria, the option vested as to 260,000 shares. On April 29, 2025, the option was modified to require only the service-based vesting requirements to continue to be satisfied in order to become fully vested; the option vested as to 520,000 shares on April 29, 2025 and the remaining 520,000 will vest in three equal annual installments, with the first such installment having occurred on October 13, 2025.
More SMMT filings
- 8-K
Filed Nov 18, 2026
- 4
Filed Nov 16, 2026
- 4
Filed Nov 16, 2026
- 8-K
Filed Nov 16, 2026
- 8-K
Filed Nov 4, 2026
- 424B7
Filed Nov 4, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.